ERBB2 and gastroesophageal junction adenocarcinoma: Overall, treatment with zolbetuximab plus CAPOX led to statistically significantly prolonged PFS and OS compared to placebo plus CAPOX in patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or mG/GEJ adenocarcinoma.